Mieszanka GLOW (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)

📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.

What Is GLOW?

GLOW is a research-grade co-formulated three-peptide blend that combines BPC-157 (Body Protection Compound 157), GHK-Cu (Glycyl-Histidyl-Lysine Copper(II) complex), and TB-500 (Thymosin Beta-4 fragment) in a single lyophilized vial at a 1:5:1 mass ratio — 10 mg BPC-157, 50 mg GHK-Cu, and 10 mg TB-500 per vial, for a total of 70 mg peptide mass. The three peptides represent three of the most cited regenerative-research compounds in the published literature, each acting on a different molecular axis: BPC-157 on local angiogenesis and growth-factor signalling, GHK-Cu on copper-mediated dermal remodelling and antioxidant signalling, and TB-500 on systemic G-actin-binding and cell migration.

The strategic rationale for the GLOW blend is complementary, non-overlapping mechanisms across three regenerative axes. Each component peptide has a distinct molecular target and tissue-distribution pattern, so co-administration covers a broader range of research endpoints than any single component alone. The blend is intended for research that benefits from simultaneous activation of all three pathways — a use case distinct from research designs that require independent dosing of each component peptide.

For research that needs independent dosing of each peptide (different doses, different schedules, different vehicle formulations), the components are also available as stand-alone vials: BPC-157, GHK-Cu, oraz TB-500. A separate three-vial bundle — the Peptydowy zestaw regeneracyjny (BPC-157 + TB-500 + bacteriostatic water shipped together as three separate vials) — provides another alternative for research requiring per-component dose-flexibility. The GLOW co-formulation is specifically for research at the fixed 1:5:1 mass ratio with single-vial reconstitution.

GLOW is supplied as a high-purity lyophilized blend for reconstitution with bacteriostatic water. The reconstituted solution retains a faint blue tint from the bound Cu²⁺ of the GHK-Cu component — a useful qualitative indicator that copper coordination remained intact through lyophilization and reconstitution. GLOW is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a combination or as any of its component peptides. The research-grade GLOW sold here is supplied tylko do użytku laboratoryjnego and is not intended for human or veterinary administration.

Mechanism of Action — Three Complementary Regenerative Pathways

What makes the GLOW co-formulation pharmacologically distinctive is the tri-axis mechanism profile — each component activates a fundamentally different regenerative pathway, and the three are non-overlapping at the molecular level. Published research on each component has established the mechanism in detail; the combination simply delivers all three in a single administration:

• BPC-157 (10 mg) — VEGF / NO / GH-receptor signalling for local tissue repair — The 15-amino-acid pentadecapeptide derived from gastric juice upregulates VEGFR2 (driving new capillary formation at injury sites), enhances endothelial nitric oxide synthase activity (protecting vascular endothelium), and increases growth-hormone receptor expression on fibroblasts and tenocytes (driving collagen synthesis). Most-cited research signal: tendon, ligament, gut barrier, and skeletal muscle recovery. Acts more locally than systemic at the injection site.
• GHK-Cu (50 mg) — copper-mediated dermal remodelling and antioxidant signalling — The Cu²⁺-coordinated tripeptide delivers copper as an enzyme cofactor for lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase (oxidative-stress buffering) while signalling on dermal fibroblasts and keratinocytes. Most-cited research signal: skin remodelling, wound healing, anti-aging in connective-tissue research, hair follicle support, copper-axis pharmacology. Higher mass loading (50 mg in the blend) reflects the larger doses typical of copper-peptide research vs the microgram-range doses of the other two components.
• TB-500 (10 mg) — G-actin sequestration and systemic cell migration — The 43-amino-acid thymic peptide is the canonical systemic regenerative compound, binding monomeric G-actin and modulating actin dynamics to drive cell migration, particularly at injury sites. Most-cited research signal: systemic muscle and cardiac recovery, vascular repair, and broad systemic distribution that complements BPC-157’s more localised action. Acts as the “systemic arm” to BPC-157’s “local arm”.

The three pathways are mechanistically complementary, not redundant: BPC-157 acts locally on the injury site, TB-500 distributes systemically and supports cell migration globally, and GHK-Cu provides copper-cofactor delivery and dermal-tissue-specific signalling. Co-administering the three in research models covers angiogenesis (BPC-157), systemic recovery (TB-500), and dermal-tissue remodelling (GHK-Cu) simultaneously — a broader research endpoint coverage than any single component alone. All three peptides have well-tolerated profiles in published preclinical research, and combination protocols are described in some published research models of multi-axis tissue regeneration.

Opublikowane zastosowania badawcze

GLOW co-formulation research is used in laboratory contexts that investigate:

• Multi-axis tissue regeneration research — preclinical models combining systemic and local regenerative endpoints; angiogenesis + cell migration + dermal remodelling in single research designs
• Wound healing research — cutaneous wound models (full-thickness, partial-thickness, burn), wound contraction kinetics, granulation tissue formation, scar-tissue characterisation; one of the more comprehensive multi-axis approaches
• Tendon, ligament, and soft-tissue recovery — rodent Achilles transection models, medial-collateral-ligament rupture research; published BPC-157 + TB-500 research literature is extensive, with the GHK-Cu addition providing copper-cofactor support for collagen cross-linking
• Skin remodelling and dermal research — collagen and elastin synthesis, dermal-fibroblast proliferation, photo-aging research; the GHK-Cu component dominates this research domain
• Comparative co-formulation research — head-to-head with stand-alone BPC-157, TB-500, oraz GHK-Cu arms; dissection of additive vs synergistic effects across the three-axis combination
• Vascular and cardiac recovery research — the combined angiogenic (BPC-157) and migratory (TB-500) signal is well-suited to vascular-recovery and cardiac-ischaemia models
• Anti-aging and longevity research — published work on copper-peptide effects in dermal and connective-tissue aging, particularly relevant for the GHK-Cu component; combined with BPC-157 + TB-500 for broader tissue-aging research designs
• Inflammation and oxidative-stress research — copper’s role as cofactor for superoxide dismutase plus the BPC-157 and TB-500 inflammation-modulating effects provide multi-axis anti-inflammatory research coverage.

For broader context, see our individual BPC-157, GHK-Cu, oraz TB-500 product pages for component-level pharmacology, the Peptydowy zestaw regeneracyjny for the alternative three-separate-vial bundle (BPC-157 + TB-500 + bacteriostatic water), and the sister copper peptide AHK-Cu for hair-axis research. Browse the full katalog peptydów badawczych w poszukiwaniu powiązanych związków.

Available Configurations

MedsBase stocks the GLOW blend in a single co-formulation: 10 mg BPC-157 + 50 mg GHK-Cu + 10 mg TB-500 per vial (1:5:1 mass ratio, 70 mg total peptide). The vial is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

All three components are supplied at ≥99% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. Because the three peptides have different research dose ranges and different roles in the blend, the 1:5:1 mass ratio is fixed at manufacture. Researchers requiring different ratios should use the stand-alone BPC-157, GHK-Cu, oraz TB-500 vials instead. Compared with purchasing the three components separately, the GLOW co-formulation offers a meaningful cost saving and the practical convenience of single-vial reconstitution at the fixed research ratio.

How It Compares — GLOW Blend vs Peptide Healing Stack

MedsBase carries two multi-peptide research products that combine the same broader healing-peptide pharmacology in different packaging formats. The choice between them depends on research design requirements:

Research designs that require flexible per-component dosing or that don’t need the copper-peptide arm should use the Peptydowy zestaw regeneracyjny. Research designs that benefit from the broader three-axis coverage (including dermal-tissue remodelling) and that are comfortable with the fixed 1:5:1 mass ratio should use the GLOW blend. Both options are pre-curated for the most-cited healing-peptide research pharmacology — the difference is packaging format and component breadth.

Przechowywanie i rekonstytucja

Przed rekonstytucją: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. The lyophilized GLOW co-formulation is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. All three component peptides have well-matched stability profiles in the lyophilized state. Avoid freeze-thaw cycles on the lyophilized powder.

Procedura rekonstytucji: inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). Because the vial contains 70 mg total peptide mass, a 2.0 mL reconstitution yields a 35 mg/mL total-peptide working concentration — equivalent to 5 mg/mL BPC-157, 25 mg/mL GHK-Cu, and 5 mg/mL TB-500. Swirl gently — do otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. shake — and allow 2–5 minutes for full dissolution. A correctly reconstituted solution should be clear with a faint blue tint from the bound Cu²⁺ of the GHK-Cu component — the colour is a useful qualitative indicator that copper coordination remained intact through lyophilization and reconstitution. Cloudiness, precipitate, or absent blue tint indicates a problem; discard and try again.

Po rekonstytucji: store refrigerated at 2–8 °C and use within 30 days for optimal stability of all three components. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity and can affect copper coordination. Protect from direct light at all times. Discard any vial showing cloudiness, precipitate, or discolouration beyond the expected faint blue tint.

Najczęściej zadawane pytania

What is GLOW used for in research?

GLOW is used in laboratory research investigating multi-axis tissue regeneration — specifically protocols that benefit from simultaneous activation of three complementary regenerative pathways (BPC-157 angiogenesis + GHK-Cu dermal remodelling + TB-500 systemic cell migration) in a single administration. Common research contexts include wound healing models, tendon and soft-tissue recovery, skin remodelling, vascular repair, anti-aging connective-tissue research, and comparative co-formulation pharmacology. The research-grade GLOW sold here is otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. FDA-approved and is supplied strictly for laboratory research use only.

What is in a GLOW vial?

Each vial contains 10 mg of BPC-157, 50 mg of GHK-Cu, and 10 mg of TB-500, co-formulated and lyophilized together as a single powder. Total peptide mass per vial: 70 mg. The 1:5:1 mass ratio reflects the different research-relevant dose ranges of the three components (BPC-157 and TB-500 are used in microgram-to-low-milligram doses; GHK-Cu is used in low-to-mid-milligram doses). All three peptides reconstitute simultaneously when bacteriostatic water is added.

How is GLOW different from the Peptide Healing Stack?

The two products combine related healing peptides but in different packaging formats. GLOW is a single vial with three peptides (BPC-157 + GHK-Cu + TB-500) co-formulated together at a fixed 1:5:1 ratio. The Peptydowy zestaw regeneracyjny is three separate vials (BPC-157 + TB-500 + bacteriostatic water) shipped in one parcel. GLOW adds the copper-peptide arm and consolidates reconstitution; the Peptide Healing Stack offers per-component dose independence without the copper-peptide component. Choose based on whether your research needs the dermal-remodelling axis (GLOW) or per-component dose flexibility (Peptide Healing Stack).

How is GLOW different from the individual component peptides?

The components are also available as stand-alone products: BPC-157, GHK-Cu, oraz TB-500. Stand-alone vials allow per-component dose control, different schedules per peptide, and different vehicle formulations per peptide. The GLOW co-formulation fixes the dose ratio at 1:5:1 mass but offers convenience (single reconstitution, single injection) and modest cost savings compared with buying the three components separately.

What is the typical GLOW research dose?

Dose depends on the research endpoint. Conservative protocols use 0.04 mL of a 35 mg/mL reconstituted solution (~200 mcg BPC-157 + 1 mg GHK-Cu + 200 mcg TB-500 per administration) several times weekly. Higher-dose protocols scale up proportionally within the fixed 1:5:1 ratio. Researchers requiring different ratios should use the stand-alone components rather than the blend.

Is GLOW FDA approved?

No. GLOW is not approved by the FDA, EMA, MHRA, or any other major regulator as a combination product. None of the three individual components (BPC-157, GHK-Cu, TB-500) have FDA approval for human therapeutic use either. GHK-Cu is incorporated into some cosmetic products under cosmetic-regulation frameworks, but none of the three peptides is approved as a drug. All GLOW sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.

Why does the GLOW solution have a blue tint?

The faint blue tint comes from the bound Cu²⁺ of the GHK-Cu component — specifically from the d-d electronic transitions of copper in the square-planar coordination environment created by the Gly-His-Lys tripeptide. The colour is a useful qualitative indicator of intact copper coordination: a properly reconstituted GLOW solution should show a faint visible blue tint; a colourless or pale solution would suggest copper loss or degradation of the GHK-Cu component. The other two peptides (BPC-157, TB-500) contribute no colour.

How should GLOW be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade peptide integrity and could disproportionately affect either copper coordination or peptide-backbone stability. Protect from direct light at all times.

How do I reconstitute GLOW?

Postępuj zgodnie z powyższą procedurą rekonstytucji. Dodaj wodę bakteriostatyczną po ściance fiolki (nie bezpośrednio na liofilizowany proszek), delikatnie obróć i odczekaj 2–5 minut do całkowitego rozpuszczenia. Nie otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. shake the vial. All three peptides reconstitute simultaneously from the same vial. A correctly reconstituted solution is clear with a faint blue tint. For a vial + 2.0 mL diluent, the working concentration is 5 mg/mL BPC-157, 25 mg/mL GHK-Cu, and 5 mg/mL TB-500.

What configurations does MedsBase stock?

MedsBase carries GLOW in a single co-formulation: 10 mg BPC-157 + 50 mg GHK-Cu + 10 mg TB-500 per vial (70 mg total peptide, 1:5:1 mass ratio, lyophilized). The vial is available in 10-vial or 20-vial pack sizes. Each component is verified individually at ≥99% HPLC purity with a certificate of analysis available on request.

Can I buy GLOW components separately instead?

Yes — MedsBase stocks all three component peptides as stand-alone products: BPC-157 in 2/5/10 mg vials, GHK-Cu, oraz TB-500 in 2/5/10 mg vials. Separate vials are useful if research protocols require dose ratios other than the fixed 1:5:1 GLOW ratio, or if researchers want different scheduling per peptide. The co-formulated GLOW blend offers convenience and cost savings for research at the 1:5:1 ratio.

Does GLOW cause side effects in research?

All three component peptides have well-tolerated profiles in published preclinical research at typical research doses. The most consistent finding for the combination is the same as for the individual components: local injection-site reactions, occasional flushing at higher doses, and (rarely) modest skin discolouration at the injection site from copper deposition (from the GHK-Cu component). Systemic adverse effects are uncommon in published preclinical literature for any of the three peptides.

How long does GLOW take to show effects in preclinical research?

Effect onset varies by research endpoint. Local wound-healing and tissue-recovery effects are typically measurable within 7–14 days of regular dosing. Skin-remodelling effects (collagen synthesis, dermal-fibroblast activity) accumulate over 4–8 weeks. Systemic regenerative effects mediated by TB-500 develop over similar timescales. The combined three-axis profile produces a broader endpoint coverage than any single component, but the kinetics for each axis follow the timeline of the respective component peptide.

Can I order GLOW for international shipping?

Yes. MedsBase ships GLOW worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy.

Other Peptides for Tissue Regeneration, Wound Healing, and Recovery Research

• BPC-157 — Body Protection Compound — the local angiogenesis component of GLOW, stand-alone vials
• GHK-Cu — Copper tripeptide — the dermal remodelling component of GLOW, stand-alone vials
• TB-500 (Tymozyna Beta-4) — Systemic healing fragment — the systemic cell migration component of GLOW
• Peptydowy zestaw regeneracyjny — Alternative three-vial bundle (BPC + TB + BAC water) without copper peptide
• AHK-Cu — Sister copper peptide to GHK-Cu — hair follicle research compound

Dalsze Materiały

Więcej opcji w Peptydach

Ranking według liczby ostatnich zamówień MedsBase — co wybierają inni klienci w tej kategorii.

BPC-157

US$115.00 – US$705.00Fascia di prezzo: da US$115.00 a US$705.00

Retatrutide

US$310.00 – US$6,515.00Fascia di prezzo: da US$310.00 a US$6,515.00

NAD⁺

US$210.00 – US$1,975.00Fascia di prezzo: da US$210.00 a US$1,975.00

CJC-1295 bez DAC

US$210.00 – US$1,975.00Fascia di prezzo: da US$210.00 a US$1,975.00